Last reviewed · How we verify
NCT05674630: TITAN-DEB
Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons
Phase 4 trial testing Magic Touch drug eluting balloon based strategy in Chronic Coronary Syndrome in 130 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Cardiocentro Ticino |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 21 February 2023 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 December 2030 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Magic Touch drug eluting balloon based strategy
- Drug-eluting stent-based strategy
Conditions studied
- Chronic Coronary Syndrome — all drugs for Chronic Coronary Syndrome →
Sponsor
Cardiocentro Ticino — full company profile →
Who can join
18 and older, any sex, with Chronic Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions. Participants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05674630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Coronary Syndrome
Currently open trials in the same condition.
- NCT07195149 — Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Followin · Phase 3 · recruiting
- NCT07182799 — Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance · active not recruiting
- NCT07291609 — Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes · recruiting
- NCT06896708 — Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patie · NA · recruiting
- NCT07020858 — FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion · recruiting
Other Cardiocentro Ticino trials
Trials by the same sponsor.
- NCT07514962 — Minimally Invasive Coronary Artery Bypass Supported by Cangrelor · recruiting
- NCT05696873 — CoPing strategIes-psyChological flexibiliTy in Patients Hospitalized for Ischemic cardiovascUlaR disEase (PICTURE) · recruiting
- NCT05751057 — The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction · NA · unknown
- NCT04164329 — Anesthetic Neurotoxicity: the Association Between General Anesthesia and the Level of Plasma Neurofilament Light · unknown
- NCT04761068 — Clinical Outcomes of Patients Undergoing CABG Surgery With VEST Supported Venous Grafts · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05674630 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cardiocentro Ticino
- Last refreshed: 8 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05674630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing